Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) PT Raised to $18 at BofA Securities
May 9, 2024 6:16 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "We raise our TEVA PO to $18 (from $16) following positive Phase 3 SOLARIS trial
update for the Olanzapine LAI [long-acting... More
